Y51.6Alpha- adrenoreceptor antagonists, not elsewhere classified
Code usage status
Primary diagnosis
Must not be used as the primary diagnosis
Apply only when it matches the confirmed diagnosis and the documented clinical record.
Specificity
Complete code in the classification
Use when the diagnosis matches and no exclusion applies.
- Group Y40-Y84
- Complications of medical and surgical care
- Official Vietnamese name
- Tác động bất lợi của chất đối kháng cảm thụ alpha- adrenalin, không phân loại mục khác
- Additional WHO coding guidance
- Excl.: ergot alkaloids (Y55.0)
Related Y51 codes
Y51
Drugs primarily affecting the autonomic nervous system
Y51.0
Anticholinesterase agents
Y51.1
Other parasympathomime tics [cholinergics]
Y51.2
Ganglionic blocking drugs, not elsewhere classified
Y51.3
Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, not elsewhere classified
Y51.4
Predominantly alpha- adrenoreceptor agonists, not elsewhere classified
Y51.5
Predominantly beta- adrenoreceptor agonists, not elsewhere classified
Y51.7
Beta- adrenoreceptor antagonists, not elsewhere classified
Y51.8
Centrally acting and adrenergic- neuron-blocking agents, not elsewhere classified
Y51.9
Other and unspecified drugs primarily affecting the autonomic nervous system
Clinical record checklist
View coding guide →- Confirm that the code matches the final documented diagnosis.
- Use one primary-diagnosis code and record only relevant additional conditions.
- Review Ministry indicators, inclusions, exclusions and notes.
- Do not infer a diagnosis beyond the clinical record.
2026 regulatory basis
Indicators are taken from columns 24–29 of the classification accompanying Circular 06/2026/TT-BYT, cross-referenced with Decision 1849/QĐ-BYT and Official Dispatch 4059/BYT-BH.
